Login
Home
Charts
Search
Watchlist
Products

Speciality Medicines Ltd

SPML·BSE
147.50-4.84%Wed, 23 Sept '26 15:28

Speciality Medicines Ltd

SPML
BSE
147.50
-4.84%
|Wed, 23 Sept '26 15:28
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
130Cr
Close
Close Price
147.50
Industry
Industry
Pharmaceuticals Bulk Drugs & Formulation
PE
Price To Earnings
11.76
PS
Price To Sales
1.72
Revenue
Revenue
75Cr
Rev Gr TTM
Revenue Growth TTM
29.21%
PAT Gr TTM
PAT Growth TTM
81.22%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
27313145
Growth YoY
Revenue Growth YoY%
11.045.4
Expenses
ExpensesCr
23262536
Operating Profit
Operating ProfitCr
5458
OPM
OPM%
17.014.317.518.6
Other Income
Other IncomeCr
0001
Interest Expense
Interest ExpenseCr
0001
Depreciation
DepreciationCr
0000
PBT
PBTCr
5458
Tax
TaxCr
0100
PAT
PATCr
5358
Growth YoY
PAT Growth YoY%
7.5205.2
NPM
NPM%
16.48.715.918.3
EPS
EPS
0.00.00.012.5
QuarterSep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
27313145
Growth YoY
Revenue Growth YoY%
11.045.4
Expenses
ExpensesCr
23262536
Operating Profit
Operating ProfitCr
5458
OPM
OPM%
17.014.317.518.6
Other Income
Other IncomeCr
0001
Interest Expense
Interest ExpenseCr
0001
Depreciation
DepreciationCr
0000
PBT
PBTCr
5458
Tax
TaxCr
0100
PAT
PATCr
5358
Growth YoY
PAT Growth YoY%
7.5205.2
NPM
NPM%
16.48.715.918.3
EPS
EPS
0.00.00.012.5

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
4023285875
Growth
Revenue Growth%
-42.518.4111.729.2
Expenses
ExpensesCr
3820224962
Operating Profit
Operating ProfitCr
245914
OPM
OPM%
5.615.319.115.618.2
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
00101
Depreciation
DepreciationCr
00000
PBT
PBTCr
235913
Tax
TaxCr
11200
PAT
PATCr
123913
Growth
PAT Growth%
14.273.7193.451.4
NPM
NPM%
3.77.310.714.817.3
EPS
EPS
4.94.77.114.120.1
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
4023285875
Growth
Revenue Growth%
-42.518.4111.729.2
Expenses
ExpensesCr
3820224962
Operating Profit
Operating ProfitCr
245914
OPM
OPM%
5.615.319.115.618.2
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
00101
Depreciation
DepreciationCr
00000
PBT
PBTCr
235913
Tax
TaxCr
11200
PAT
PATCr
123913
Growth
PAT Growth%
14.273.7193.451.4
NPM
NPM%
3.77.310.714.817.3
EPS
EPS
4.94.77.114.120.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025
Equity Capital
Equity CapitalCr
0456
Reserves
ReservesCr
221024
Current Liabilities
Current LiabilitiesCr
4677
Non Current Liabilities
Non Current LiabilitiesCr
0113
Total Liabilities
Total LiabilitiesCr
6132340
Current Assets
Current AssetsCr
4112136
Non Current Assets
Non Current AssetsCr
2224
Total Assets
Total AssetsCr
6132340
Financial YearMar 2022Mar 2023Mar 2024Mar 2025
Equity Capital
Equity CapitalCr
0456
Reserves
ReservesCr
221024
Current Liabilities
Current LiabilitiesCr
4677
Non Current Liabilities
Non Current LiabilitiesCr
0113
Total Liabilities
Total LiabilitiesCr
6132340
Current Assets
Current AssetsCr
4112136
Non Current Assets
Non Current AssetsCr
2224
Total Assets
Total AssetsCr
6132340

Cash Flow

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1-4-5-6-1
Investing Cash Flow
Investing Cash FlowCr
-200-2-3
Financing Cash Flow
Financing Cash FlowCr
245828
Net Cash Flow
Net Cash FlowCr
000124
Free Cash Flow
Free Cash FlowCr
-1-4-5-6
CFO To PAT
CFO To PAT%
54.5-249.6-163.6-67.3-9.8
CFO To EBITDA
CFO To EBITDA%
35.4-118.2-91.2-63.7-9.4
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1-4-5-6-1
Investing Cash Flow
Investing Cash FlowCr
-200-2-3
Financing Cash Flow
Financing Cash FlowCr
245828
Net Cash Flow
Net Cash FlowCr
000124
Free Cash Flow
Free Cash FlowCr
-1-4-5-6
CFO To PAT
CFO To PAT%
54.5-249.6-163.6-67.3-9.8
CFO To EBITDA
CFO To EBITDA%
35.4-118.2-91.2-63.7-9.4

Ratios

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
130
Price To Earnings
Price To Earnings
11.8
Price To Sales
Price To Sales
1.7
Price To Book
Price To Book
1.8
EV To EBITDA
EV To EBITDA
8.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
13.029.433.627.4
OPM
OPM%
5.615.319.115.618.218.2
NPM
NPM%
3.77.310.714.817.317.3
ROCE
ROCE%
69.634.628.825.8
ROE
ROE%
76.628.819.528.3
ROA
ROA%
25.612.712.921.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
130
Price To Earnings
Price To Earnings
11.8
Price To Sales
Price To Sales
1.7
Price To Book
Price To Book
1.8
EV To EBITDA
EV To EBITDA
8.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
13.029.433.627.4
OPM
OPM%
5.615.319.115.618.218.2
NPM
NPM%
3.77.310.714.817.317.3
ROCE
ROCE%
69.634.628.825.8
ROE
ROE%
76.628.819.528.3
ROA
ROA%
25.612.712.921.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Speciality Medicines Ltd

  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/d5svy6q647ut3tillomem2b9.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/5y7ynwhbrpva5jdvtw450ve5.pdf